184 related articles for article (PubMed ID: 35078286)
1. [Immune Checkpoint Inhibitors Related Diabetes Mellitus:
A Report of 2 Cases and Literature Review].
Ren Y; Zhang L; Wang Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):61-65. PubMed ID: 35078286
[TBL] [Abstract][Full Text] [Related]
2. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
Ning P; Liu S; Cao H
J Med Case Rep; 2024 Jan; 18(1):51. PubMed ID: 38247005
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
4. [IMMUNE CHECKPOINT INHIBITOR-INDUCED DIABETES MELLITUS].
Fischer M; Amos S; Levy L; Pollack R
Harefuah; 2021 Oct; 160(10):657-662. PubMed ID: 34689435
[TBL] [Abstract][Full Text] [Related]
5. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
Zhang Z; Sharma R; Hamad L; Riebandt G; Attwood K
Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism.
Mourad D; Azar NS; Eid AA; Azar ST
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672515
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
[TBL] [Abstract][Full Text] [Related]
8. Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus.
Shen M; Chen D; Zhao R; Zheng X; Gu Y; Yang T; Shi Y
Front Endocrinol (Lausanne); 2023; 14():1213225. PubMed ID: 37554766
[TBL] [Abstract][Full Text] [Related]
9. Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review.
Huang W; Liu Y; Li M; Xue Y; Bao W; Guo Y
Medicine (Baltimore); 2023 Nov; 102(45):e35946. PubMed ID: 37960733
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
11. Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy.
Bastin M; Mosbah H; Carlier A; Boudifa A; Villemain A; Hartemann A; Andreelli F
Diabetes Metab; 2020 Oct; 46(5):406-407. PubMed ID: 31034979
[No Abstract] [Full Text] [Related]
12. Diabetes mellitus induced by immune checkpoint inhibitors.
Zheng Z; Liu Y; Yang J; Tan C; Zhou L; Wang X; Xiao L; Zhang S; Chen Y; Liu X
Diabetes Metab Res Rev; 2021 Jan; 37(1):e3366. PubMed ID: 32543027
[TBL] [Abstract][Full Text] [Related]
13. [Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors
Combined with Chemotherapy].
Xiao P; Zhang L; Wang Y; Meng F; Wang X; Zhong D
Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):287-290. PubMed ID: 35477193
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review.
Fang W; Gao Y; Shi X; Zhang X; Zhou S; Zhu H; Yan W; Wang H
Front Immunol; 2023; 14():1243773. PubMed ID: 37841238
[TBL] [Abstract][Full Text] [Related]
15. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
Seo JH; Lim T; Ham A; Kim YA; Lee M
Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
17. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
Okubo M; Hataya Y; Fujimoto K; Iwakura T; Matsuoka N
J Diabetes Investig; 2023 Jan; 14(1):147-150. PubMed ID: 36251515
[TBL] [Abstract][Full Text] [Related]
18. Chronic hyperglycemia based on diabetes is independently associated with decreased survival in patients with advanced cancer treated with immune checkpoint inhibitors.
Yekedüz E; Köksoy EB; Yazgan SC; Karataş G; Şenler FÇ; Utkan G; Akbulut H; Demirkazik A; Ürün Y
Anticancer Drugs; 2022 Nov; 33(10):1145-1149. PubMed ID: 35946564
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.
Wen YP; Xiao HW; Yin JH; Guo HR; Shan MJ; Shen LP; Liu LS
Medicine (Baltimore); 2022 Dec; 101(48):e32076. PubMed ID: 36482651
[TBL] [Abstract][Full Text] [Related]
20. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
